Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline.
is resource is a practice tool based on ASCO
®
practice guidelines and is not intended to substitute for the
independent professional judgment of the treating physician. Practice guidelines do not account for individual
variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment.
Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are
available at www.asco.org/hematologic-malignancies-guidelines. Copyright ©2019 by American Society of Clinical
Oncolog y. All rights reserved.
Source
Shapiro CL, Lacchetti C, Neuner J. Management of Osteoporosis in Survivors of Adult Cancers
With Nonmetastatic Disease: ASCO Clinical Practice Guideline Summary. Journal of Oncology
Practice. September 2019. doi:10.1200/jop.19.00427.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2019 All rights reserved.
ASCOOST1993
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/survivorship-guidelines.
Abbreviations
AI, aromatase inhibitor; ADT, androgen deprivation therapy; BMD, bone mineral density;
CIOF, chemotherapy-induced ovarian failure; DXA, dual X-ray absorptiometry; GnRH,
gonadotropin releasing hormones; IV, intravenous; MRONJ, medication-related osteonecrosis
of the jaw; SQ, subcutaneous
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
EP
Expert
panel
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient